Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 1, 2001AIDS

Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012)

View Full Paper
Ask AI
Bookmark
Share

Authors

SESusan H. EshlemanJohns Hopkins UniversityMMMartin MracnaJohns Hopkins UniversityLGLaura GuayRutgers, The State University of New Jersey

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Eshleman et al. (2001) studied this question.

synapsesocial.com/papers/6a74764eb35e02fb150324eahttps://doi.org/10.1097/00002030-200110190-00006
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission2000 · 213 citations
  2. 2Pharmacokinetics of Nevirapine in Human Immunodeficiency Virus Type 1-Infected Pregnant Women and Their Neonates1998 · 197 citations
  3. 3Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy1994 · 579 citations
  4. 4Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial1999 · 1,652 citations
  5. 5A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006)1999 · 215 citations